Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)‘s stock had its “buy” rating restated by stock analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Monday. They presently have a $76.00 price objective on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price target would indicate a potential upside of 15.47% from the stock’s previous close.

Several other equities research analysts have also issued reports on the stock. Janney Montgomery Scott lowered shares of Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 26th. Cann reiterated a “buy” rating and set a $75.00 target price on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Oppenheimer Holdings, Inc. set a $75.00 target price on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, June 1st. Finally, BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $75.20.

Agios Pharmaceuticals (AGIO) opened at 65.82 on Monday. The firm has a 50-day moving average of $60.83 and a 200 day moving average of $54.73. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $67.74. The firm’s market capitalization is $3.19 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. During the same quarter in the previous year, the firm earned ($1.47) earnings per share. The company’s revenue for the quarter was up 62.1% compared to the same quarter last year. Equities research analysts forecast that Agios Pharmaceuticals will post ($7.07) earnings per share for the current year.

WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/agios-pharmaceuticals-inc-agio-stock-rating-reaffirmed-by-j-p-morgan-chase-co/1574756.html.

In related news, Director Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $65.47, for a total value of $65,470.00. Following the transaction, the director now directly owns 86,394 shares of the company’s stock, valued at $5,656,215.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David P. Schenkein sold 27,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the completion of the transaction, the chief executive officer now directly owns 3,000 shares in the company, valued at $179,850. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 99,938 shares of company stock valued at $6,009,912. Company insiders own 10.55% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Lord Abbett & CO. LLC increased its stake in shares of Agios Pharmaceuticals by 81.5% in the second quarter. Lord Abbett & CO. LLC now owns 266,910 shares of the biopharmaceutical company’s stock worth $13,733,000 after buying an additional 119,836 shares during the period. Public Employees Retirement System of Ohio increased its stake in shares of Agios Pharmaceuticals by 52.8% in the second quarter. Public Employees Retirement System of Ohio now owns 18,353 shares of the biopharmaceutical company’s stock worth $944,000 after buying an additional 6,338 shares during the period. California State Teachers Retirement System increased its stake in shares of Agios Pharmaceuticals by 20.7% in the second quarter. California State Teachers Retirement System now owns 74,157 shares of the biopharmaceutical company’s stock worth $3,816,000 after buying an additional 12,716 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 3,123 shares during the period. Finally, State Street Corp increased its stake in shares of Agios Pharmaceuticals by 8.1% in the second quarter. State Street Corp now owns 1,302,966 shares of the biopharmaceutical company’s stock worth $67,036,000 after buying an additional 97,220 shares during the period. 94.40% of the stock is currently owned by institutional investors.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.